PHARMACOKINETICS OF QUINOLONES - NEWER ASPECTS

被引:44
作者
WOLFSON, JS
HOOPER, DC
机构
[1] Infectious Disease Unit, Medical Services, Massachusetts General Hospital, Boston, 02114, Massachusetts
关键词
D O I
10.1007/BF01967000
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Differences in pharmacokinetic properties are emerging as important determinants in distinguishing among clinical uses of individual new quinolone antimicrobial agents. Selected data on pharmacokinetics, new pharmacokinetic studies, and pharmacodynamics are reviewed, with reference to norfloxacin, ciprofloxacin, ofloxacin, pefloxacin, enoxacin, fleroxacin, lomefloxacin, and other new quinolones. Considering pharmacokinetics, oral bioavailability is excellent (> 95 %) for most quinolones. Differences in peak serum concentrations and beta-half-lives of elimination exist, however, and are reflected in up to ten-fold differences in values of the area under the curve of serum concentration versus time for administration of similar drug doses. As suggested by high apparent volumes of distribution and low binding to serum proteins, penetration into many body tissues and fluids is favorable. Considering new findings, orally administered ciprofloxacin has been found to be absorbed primarily in the duodenum and jejunum. Studies also suggest this drug to be cleared by transepithelial elimination into the bowel lumen as well as by the renal route. Oral bioavailability of quinolones has been demonstrated to be in general good in ill as well as healthy subjects but is reduced on co-administration with magnesium- and aluminum-containing acids, sucralfate (which contains aluminum), or ferrous sulfate. Pharmacodynamic parameters, such as the relationship of serum concentrations and drug potency in vitro to clinical response and suppression of bacterial resistance, have been little studied and merit further investigation.
引用
收藏
页码:267 / 274
页数:8
相关论文
共 84 条
  • [31] INHIBITION OF THEOPHYLLINE CLEARANCE BY COADMINISTERED OFLOXACIN WITHOUT ALTERATION OF THEOPHYLLINE EFFECTS
    GREGOIRE, SL
    GRASELA, TH
    FREER, JP
    TACK, KJ
    SCHENTAG, JJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (03) : 375 - 378
  • [32] GRIMM H, 1987, AM J MED, V82, P376
  • [33] STEADY-STATE PHARMACOKINETICS OF FLEROXACIN IN PATIENTS WITH SKIN AND SKIN STRUCTURE INFECTIONS
    HEIMDUTHOY, K
    PELTIER, G
    AWNI, W
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) : 922 - 923
  • [34] MULTICENTER INVITRO EVALUATION OF LOMEFLOXACIN (NY-198, SC-47111), INCLUDING TESTS AGAINST NEARLY 7,000 BACTERIAL ISOLATES AND PRELIMINARY RECOMMENDATIONS FOR SUSCEPTIBILITY TESTING
    JONES, RN
    ALDRIDGE, KE
    BARRY, AL
    FUCHS, PC
    GERLACH, EH
    PFALLER, MA
    WASHINGTON, JA
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1988, 10 (04) : 221 - 240
  • [35] COMPARISON OF HIGH-PRESSURE LIQUID-CHROMATOGRAPHY AND BIOASSAY FOR DETERMINATION OF CIPROFLOXACIN IN SERUM AND URINE
    JOOS, B
    LEDERGERBER, B
    FLEPP, M
    BETTEX, JD
    LUTHY, R
    SIEGENTHALER, W
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (03) : 353 - 356
  • [36] INFLUENCE OF LOMEFLOXACIN ON THE PHARMACOKINETICS OF THEOPHYLLINE
    LEBEL, M
    VALLEE, F
    STLAURENT, M
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) : 1254 - 1256
  • [37] LEBEL M, 1988, ISI ATLAS-PHARMACOL, V2, P196
  • [38] LEBEL M, 1988, PHARMACOTHERAPY, V8, P3
  • [39] THE PHARMACOKINETICS AND TISSUE PENETRATION OF OFLOXACIN
    LOCKLEY, MR
    WISE, R
    DENT, J
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1984, 14 (06) : 647 - 652
  • [40] PHARMACOKINETICS OF OFLOXACIN AFTER PARENTERAL AND ORAL-ADMINISTRATION
    LODE, H
    HOFFKEN, G
    OLSCHEWSKI, P
    SIEVERS, B
    KIRCH, A
    BORNER, K
    KOEPPE, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (09) : 1338 - 1342